Try our Advanced Search for more refined results

MYLAN PHARMACEUTICALS, INC. v. CELGENE CORPORATION

Track this case

Case overview

Case Number:

2:14-cv-02094

Court:

New Jersey

Nature of Suit:

Anti-Trust

Judge:

Esther Salas

Firms

Companies

Government Agencies

Sectors & Industries:

  1. July 31, 2019

    Celgene To Pay $62M To End Antitrust Suit Over Cancer Drugs

    Pharmaceutical company Celgene Corp. has agreed to fork over $62 million to resolve claims that it has suppressed competition for the brand-name cancer drugs Thalomid and Revlimid by preventing lower-priced generic versions from entering the market.

  2. January 14, 2019

    Mylan Fights To Put Consumer On Stand In Celgene Clash

    Mylan told a New Jersey federal court Friday that a consumer witness should be allowed to testify in its suit accusing Celgene of stifling generic competition for two cancer drugs because Celgene already has most of the information it needs from him.

  3. December 18, 2018

    Celgene Wants Mylan Sanctioned For Bid To Add Witnesses

    Celgene Corp. urged a New Jersey federal judge Tuesday to reject Mylan Pharmaceuticals Inc.'s bid to add three consumer witnesses in its antitrust case against Celgene over cancer drugs Thalomid and Revlimid, or at least sanction Mylan through attorneys' fees and costs in connection with additional discovery related to the witnesses.

  4. November 28, 2018

    Mylan Pushes For Consumer Witnesses In Battle With Celgene

    Mylan Pharmaceuticals has urged a New Jersey federal judge to allow it to add three consumer witnesses in its case accusing Celgene Corp. of stifling generic competition for the brand-name cancer drugs Thalomid and Revlimid, saying they can testify about the scheme's impact on drug prices.

  5. February 02, 2018

    Mylan Says Celgene Claims Still Timely In Antitrust Suit

    Mylan Pharmaceuticals Inc.'s antitrust lawsuit accusing Celgene Corp. of stifling generic competition for the brand-name cancer drug Thalomid isn't barred by the four-year statute of limitations because the clock didn't begin ticking until the damages were "reasonably concrete and measurable," the generic-drug maker told a federal judge Thursday.

  6. December 13, 2017

    Partial Win Likely For Celgene In Mylan Antitrust Suit

    A New Jersey federal judge indicated Wednesday that she would give Celgene Corp. a partial win in an antitrust suit from Mylan Pharmaceuticals Inc. over cancer drugs Thalomid and Revlimid, saying Celgene likely could be held liable for its conduct after Mylan received approval of testing protocols but not before.

  7. March 06, 2015

    3rd Circ. Declines To Hear Mylan, Celgene Antitrust Fight

    The Third Circuit on Thursday rejected Celgene Corp.'s bid for an immediate review of a New Jersey federal judge's decision not to toss Mylan Pharmaceuticals Inc.'s antitrust suit accusing Celgene of gaming federal drug safety measures to block lower-priced generic versions of its blockbuster cancer drugs Thalomid and Revlimid.

  8. June 19, 2014

    FTC Warns REMS Abuse Not Safe From Antitrust Law

    The Federal Trade Commission warned in an amicus filing in New Jersey federal court Tuesday that generic-drug makers should be allowed to sue brand-name companies under antitrust laws for allegedly gaming federal drug safety measures — known as risk evaluation and mitigation strategies programs — in Mylan Pharmaceuticals Inc.'s antitrust suit against Celgene Corp.

  9. April 04, 2014

    Mylan Claims Celgene Is Blocking Cancer Drug Generics

    Mylan Pharmaceuticals Inc. on Thursday filed an antitrust suit against Celgene Corp. in New Jersey federal court, accusing Celgene of maintaining monopolies over the markets for its blockbuster cancer drugs Thalomid and Revlimid by preventing the launch of lower-priced generic versions.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!